Trimethaphan may increase the hypotensive activities of Phentolamine. The serum concentration of Lamotrigine can be decreased when it is combined with Hexobarbital. The risk or severity of adverse effects can be increased when Bupropion is combined with Fluvoxamine. The risk or severity of adverse effects can be increased when Esmolol is combined with Atenolol. The serum concentration of Miconazole can be increased when it is combined with Mifepristone. Piroxicam may decrease the excretion rate of Sabarubicin which could result in a higher serum level. Metronidazole may increase the QTc-prolonging activities of Ibutilide. Aldosterone may increase the hypokalemic activities of Hydroflumethiazide. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perazine. The serum concentration of Chlorotrianisene can be decreased when it is combined with Moexipril. The serum concentration of Droxicam can be increased when it is combined with Probenecid. The serum concentration of Procainamide can be increased when it is combined with Cimetidine. Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Flecainide can be increased when it is combined with Darunavir. The serum concentration of Clonidine can be decreased when it is combined with Teriflunomide. The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Felbinac. Indacaterol may increase the hypokalemic activities of Beclomethasone dipropionate. The serum concentration of Methylphenobarbital can be increased when it is combined with Quazepam. The serum concentration of Busulfan can be increased when it is combined with Metronidazole. Dextroamphetamine may decrease the sedative activities of Thonzylamine. The metabolism of Leflunomide can be increased when combined with Secobarbital. The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Salmonella typhi ty21a live antigen. The therapeutic efficacy of Calcitriol can be decreased when used in combination with Flurandrenolide. The metabolism of Morphine can be decreased when combined with Cimetidine. The serum concentration of Promazine can be increased when it is combined with Sulfametopyrazine. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Norethisterone. The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasone. Antipyrine may increase the anticoagulant activities of Citric Acid. The serum concentration of Cerivastatin can be increased when it is combined with Dimethyl sulfoxide. The risk or severity of adverse effects can be increased when Diclofenac is combined with Indomethacin. The risk or severity of adverse effects can be increased when Propantheline is combined with Hyoscyamine. Guanadrel may increase the hypotensive activities of Losartan. The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methadyl Acetate. Rapacuronium may increase the adverse neuromuscular activities of Estrone. The metabolism of Antipyrine can be decreased when combined with Crisaborole. The serum concentration of Netilmicin can be decreased when it is combined with Cloxacillin. The risk or severity of adverse effects can be increased when Rofecoxib is combined with Phenylbutazone. Acetylsalicylic acid may increase the anticoagulant activities of Heparin. Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. The therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Neostigmine. The bioavailability of Fluprednidene can be decreased when combined with Magnesium oxide. The serum concentration of Tianeptine can be increased when it is combined with Quinapril. The metabolism of Solifenacin can be decreased when combined with Tavaborole. The risk or severity of adverse effects can be increased when Diclofenac is combined with E-6201. The serum concentration of Fluocinonide can be increased when it is combined with Diethylstilbestrol. The metabolism of Dextropropoxyphene can be decreased when combined with Voriconazole. The risk or severity of adverse effects can be increased when Verapamil is combined with Irbesartan. The serum concentration of Testosterone can be increased when it is combined with Stiripentol. The bioavailability of Fluticasone furoate can be decreased when combined with Magnesium Hydroxide. Debrisoquin may increase the hypotensive activities of Chlorothiazide. Salmeterol may increase the QTc-prolonging activities of Ofloxacin. The risk or severity of adverse effects can be increased when Tetracaine is combined with Cetirizine. Valsartan may increase the hypotensive activities of Guanadrel. The serum concentration of Safinamide can be increased when it is combined with Simeprevir. The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Atazanavir. The serum concentration of Clonidine can be decreased when it is combined with Lumacaftor. Ferulic acid may increase the hyperkalemic activities of Drospirenone. The therapeutic efficacy of Pramlintide can be decreased when used in combination with Drospirenone. The risk or severity of adverse effects can be increased when Levosalbutamol is combined with Atorvastatin. Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The risk or severity of adverse effects can be increased when Valsartan is combined with Esmolol. Thioproperazine may increase the hypotensive activities of Timolol. The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiopental. The serum concentration of Avanafil can be increased when it is combined with Ketoconazole. The risk or severity of adverse effects can be increased when Flurazepam is combined with Brompheniramine. Phenoxybenzamine may increase the hypotensive activities of Rescinnamine. Aluminum hydroxide can cause a decrease in the absorption of Demeclocycline resulting in a reduced serum concentration and potentially a decrease in efficacy. The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Desonide. The serum concentration of Ubidecarenone can be increased when it is combined with Sulfanilamide. Butylscopolamine may increase the anticholinergic activities of Umeclidinium. The therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Phosphate. The risk or severity of adverse effects can be increased when Nystatin is combined with Barnidipine. Ramipril may increase the hypotensive activities of Manidipine. The risk or severity of adverse effects can be increased when Methohexital is combined with Hexobarbital. The serum concentration of Ergotamine can be increased when it is combined with Mifepristone. The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acetazolamide. Irbesartan may increase the hypotensive activities of Manidipine. The risk or severity of adverse effects can be increased when Semapimod is combined with Prednisolone. Meloxicam may decrease the antihypertensive activities of Aliskiren. The risk or severity of adverse effects can be increased when Fosinopril is combined with Diclofenac. Dihydroergotamine may increase the hypertensive activities of Dobutamine. Aliskiren may increase the hyperkalemic activities of Cilazapril. The serum concentration of Tolvaptan can be increased when it is combined with Miconazole. Carvedilol may increase the hypotensive activities of Guanethidine. The risk or severity of adverse effects can be increased when Sirolimus is combined with Lisinopril. The metabolism of Tacrolimus can be decreased when combined with Olaparib. The risk or severity of adverse effects can be increased when Naproxen is combined with Parthenolide. The metabolism of Estradiol can be decreased when combined with Lidocaine. The risk or severity of adverse effects can be increased when Betaxolol is combined with Nesiritide. The risk or severity of adverse effects can be increased when Indomethacin is combined with Prasterone sulfate. Tolmetin may decrease the excretion rate of Daunorubicin which could result in a higher serum level. The serum concentration of Delavirdine can be decreased when it is combined with Sitagliptin. The metabolism of Fluticasone furoate can be increased when combined with Rifampicin. The risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Meprobamate. Arformoterol may increase the hypokalemic activities of Bendroflumethiazide. The metabolism of Nebivolol can be decreased when combined with Primaquine. Hexobarbital may increase the hypotensive activities of Bisoprolol. The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene. The risk or severity of adverse effects can be increased when Spirapril is combined with Meclofenamic acid. The metabolism of Diclofenac can be decreased when combined with Irbesartan. Amobarbital may increase the hypotensive activities of Quinapril. The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Acetylsalicylic acid. The risk or severity of adverse effects can be increased when Pargyline is combined with Pirbuterol. The therapeutic efficacy of Terbinafine can be decreased when used in combination with Sarilumab. Fibrinolysin may increase the anticoagulant activities of Phenprocoumon. Piroxicam may increase the neuroexcitatory activities of Norfloxacin. The risk or severity of adverse effects can be increased when Fentanyl is combined with Halazepam. The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dapagliflozin. Dihydralazine may increase the hypotensive activities of Phentolamine. The risk or severity of adverse effects can be increased when Trandolapril is combined with Indomethacin. The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Beclomethasone dipropionate. The serum concentration of Ergotamine can be increased when it is combined with Vildagliptin. The risk or severity of adverse effects can be increased when Secobarbital is combined with Clobazam. The metabolism of Lorcaserin can be decreased when combined with Cyclosporine. Antipyrine may decrease the antihypertensive activities of Nadolol. The risk or severity of adverse effects can be increased when Ferulic acid is combined with Cortisone acetate. The serum concentration of Lamotrigine can be increased when it is combined with Cimetidine. The risk or severity of adverse effects can be increased when Azelastine is combined with Nitroaspirin. Trandolapril may increase the hypotensive activities of Cafedrine. The serum concentration of Atorvastatin can be increased when it is combined with Mifepristone. The risk or severity of adverse effects can be increased when Atenolol is combined with Eplerenone. The risk or severity of adverse effects can be increased when Clonidine is combined with Tetrabenazine. The risk or severity of adverse effects can be increased when Reserpine is combined with Alaproclate. The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Dexamethasone. Difluocortolone may increase the hypokalemic activities of Hydroflumethiazide. Dihydralazine may increase the hypotensive activities of Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Tizanidine is combined with Brompheniramine. Pefloxacin may increase the hypoglycemic activities of Alogliptin. Dihydroergotamine may increase the hypertensive activities of Solabegron.